

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/SE04/001911

International filing date: 17 December 2004 (17.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: SE
Number: 0303397-4
Filing date: 17 December 2003 (17.12.2003)

Date of receipt at the International Bureau: 07 January 2005 (07.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

PCT / SE 2004 / 0 0 1 9 1 1

Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.




(71) Sökande InDex Pharmaceuticals AB, Stockholm SE
Applicant (s)

(21) Patentansökningsnummer 0303397-4
Patent application number

(86) Ingivningsdatum 2003-12-17
Date of filing

Stockholm, 2004-12-21

För Patent- och registreringsverket
For the Patent- and Registration Office


Görel Gustafsson

Avgift
Fee

**PATENT- OCH
REGISTRERINGSVERKET**
SWEDEN

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

COMPOUNDS AND METHOD FOR RNA INTERFERENCE

FIELD OF THE INVENTION

The present invention concerns compositions and methods useful in modulating gene expression associated with inflammation and allergic responses. More specifically, the invention relates to short interfering nucleic acid molecules (siRNA) capable of mediating RNA interference (RNAi) against the p65 subunit of the transcription factor NF-kappa-B, as well as pharmaceutical compositions thereof and methods for their use as a therapeutic for the treatment of inflammatory and allergic type diseases.

10 BACKGROUND OF THE INVENTION

Nuclear factor kappa B (NF-kappa-B) is a member of the Rel/NF-kappa-B family of inducible pleiotropic transcription factors that play a pivotal role in a wide array of physiological and pathological responses including immune modulation, inflammatory responses, cancer and apoptosis. This extraordinary degree of involvement results from the ability of such inducible transcription factors to control the expression of a large multitude of various key genes involved in cellular processes. Consequently, there has been intense scientific activity in the NF-kappa-B field that has provided increasing evidence that NF-kappa-B is a major, if not the major transcription factor regulating inflammation and immunity.

20 In mammals the Rel/NF-kappa-B family consists of some 5 identified proteins, NF-kappa-B1 (p50 & precursor protein p105), NF-kappa-B2 (p52 & precursor protein p100), p65 (RelA), c-Rel, and RelB. The most prevalent form of NF-kappa-B heterodimer consists of a p50 subunit and a p65 subunit and is found in the cytoplasm of most cell types. By convention, any homo- or heterodimer is termed NF-kappa-B. The inactive NF-kappa-B dimer is present in the cytosol bound to inhibitory proteins termed inhibitor protein I-kappa B (Ikb), to which there are seven known types, the most important being I-kappa-B-alpha and I-kappa-B-beta.

Activators of NF-kappa B, such as lipopolysaccharide (LPS) and TNF-alpha, induce site-specific phosphorylation of I-kappa B and consecutive rapid dissociation of the complex accompanied by proteolytic degradation of I-kappa B. The released NF-kappa-B subsequently translocates from the cytosol into the
5 nucleus where it binds to specific sequence elements and activates the transcription of a whole multitude of diverse genes with diverse functions.

Many pro-inflammatory cytokine genes have NF-kappa-B binding sites, and as a result inhibition of NF-kappa-B driven transcription is likely to be a pivotal element in the pathogenesis of various inflammatory type diseases, cancer, immune
10 modulation and apoptosis. Some of these induced proteins can in turn activate NF-kappa-B leading to the further amplification and perpetuation of the inflammatory response. Recently, NF-kappa-B has been shown to have an anti-apoptotic role in certain cell types, most likely by inducing the expression of anti-apoptotic genes. This function may protect tumor cells against anti-cancer
15 treatments and opens the possibility to use NF-kappa-B inhibiting compounds to sensitize the tumor cells and to improve the efficiency of the anti-cancer treatment.

Due to NF-kappa-B's direct role in regulating responses to inflammatory cytokines, it is perhaps not surprising that it plays an important role in the
20 development of various diseases such as chronic inflammatory diseases such as rheumatoid arthritis, asthma and inflammatory bowel disease; acute diseases such as septic shock; Alzheimer's disease where the ss-amyloid protein activates NF-KB; atherosclerosis, where NF-kappa-B may be activated by oxidized lipids; autoimmune disease such as systemic lupus erythematosus; cancer by up-
25 regulating certain oncogenes or by preventing apoptosis. In addition, NF-kappa-B is also involved in viral infection since NF-kappa-B is activated by different viral proteins, such as occurs upon infection with rhinovirus, influenza virus, Epstein-Barr virus, HTLV, cytomegalovirus or adenovirus. Furthermore, several viruses such as HIV have NF-kappa-B binding sites in their promoter/enhancer regions.

- Because of the potential role of NF-kappa-B in many of the above-mentioned diseases, NF-kappa-B and its regulators have drawn much interest as targets for the treatment of NF-KB related diseases. Glucocorticoids are effective inhibitors of NF-kappa-B, but they have endocrine and metabolic side effects when given systematically. Antioxidants may represent another class of NF-kappa-B inhibitors, but currently available antioxidants such as acetylcysteine are relatively weak and unspecific. However many compounds that have demonstrated inhibitory properties against NF-kappa-B have not been successfully developed as potential drugs due to the often serious nature of unwanted effects.
- Consequently there is an obvious need for new compounds that are able to achieve effective and specific inhibition of NF-kappa-B without being compromised by serious unwanted side effects. Such compounds are the subject of this application.

RNA interference

- The following is a discussion of relevant art pertaining to RNA interference (RNAi). The discussion is provided only for understanding of the invention that follows. The summary is not an admission that any of the work described below is prior art to the claimed invention.

- RNAi is a sequence-specific gene silencing process induced by double-stranded RNA (dsRNA). RNAi is a natural mechanism, which can also be used to provide information about gene function quickly, easily, and inexpensively. The use of RNAi for genetic-based therapies is widely studied, especially in viral infections, cancers, and inherited genetic disorders. RNAi has been used to make tissue-specific knockdown mice for studying gene function in a whole animal. Combined with genomics data, RNAi-directed gene silencing could allow functional determination of any gene expressed in a cell or pathway.

The term "RNA interference" (RNAi) was first coined after the discovery that injection of dsRNA into the nematode *C. elegans* leads to specific silencing of

genes highly homologous in sequence to the delivered dsRNA (Fire et al., 1998, Nature, 391,806). RNAi was subsequently later observed to function in insects, frogs, and other animals including mice.

RNA interference (RNAi) describes a phenomenon wherein double-stranded
5 RNA (dsRNA), when present inside a cell, inhibits expression of an edogenous gene that has an identical or nearly identical sequence to that of the dsRNA. Inhibition is caused by the specific degradation of the messenger RNA (mRNA) transcribed from the target gene. In greater detail, RNA interference describes a process of sequence-specific post-transcriptional gene silencing in animals
10 mediated by so called "short interfering RNAs" (siRNAs) (Fire et al., 1998).

The natural function of RNAi appears to be protection of the genome against invasion by mobile genetic elements such as retrotransposons and viruses which produce aberrant RNA or dsRNA in the host cell when they become active (Jensen et al., 1999; Ketting et al., 1999; Ratcliff et al., 1999; Tabara et al.,
15 1999). The process of post-transcriptional gene silencing is therefore believed to be an evolutionarily-conserved cellular defense mechanism present in the majority of mammalian cell types and is used to prevent the expression of foreign genes such as those derived from infection of viruses. This assumption is further strengthened by the observation that RNAi in animals, and the related
20 phenomena of Post-transcriptional gene silencing (PTGS) in plants, result from the same highly conserved mechanism, indicating an ancient origin.

The basic process involves a dsRNA that is processed by cleavage into shorter units (called short interfering RNA; siRNA) that guide recognition and targeted cleavage of homologous target messenger RNA (mRNA).
25

The currently known mechanism of RNAi can be described as follows:

The processing of dsRNA into siRNAs, which in turn induces degradation of the intended target mRNA, is a two-step RNA degradation process. The first step

involves a dsRNA endonuclease (ribonuclease III-like; RNase III-like) activity that processes dsRNA into smaller sense and antisense RNAs which are most often in the range of 21 to 25 nucleotides (nt) long, giving rise to the so called short interfering RNAs (siRNAs). This RNase III-type protein is termed "Dicer". In a
5 second step, the antisense siRNAs produced combine with, and serve as guides for, a different ribonuclease complex called RNA-induced silencing complex (RISC), which cleaves the target homologous single-stranded mRNAs. Cleavage of the target mRNA has been observed to place in the middle of the duplex region complementary to the antisense strand of the siRNA duplex and the
10 intended target mRNA.

While these studies and others indicate that there are certain requirements that need to be fulfilled in order to mediate efficient RNAi activity, such as length of the RNAi as measured in nucleotide bases, structure, chemical composition, and indeed even the sequence, there is no general agreement as to the
15 characteristics of an effective RNAi construct. The issues of specificity, efficacy, and side effects need to be handled on a case-by-case basis.

Chemical modifications have been addressed through the work of Kreutzer *et al.*, (see the published international patent application WO 00/44895) describing certain chemical modifications for use in dsRNA constructs in order to prevent
20 activation of double-stranded RNA-dependent protein kinase PKR, specifically 2'-amino or 2'-O- methyl nucleotides, and nucleotides containing a 2'-O or 4'-C methylene bridge.

Longer dsRNA have also been the subject of investigations, as for example in the work of Beach *et al.*, see the published international patent application WO
25 01/68836. The authors describe specific methods for blocking gene expression using endogenously-derived dsRNA.

SUMMARY OF THE INVENTION

This invention relates to compounds, compositions, and methods useful for modulating the expression and activity of NF-kappa-B by RNA interference (RNAi) using small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA) and double-stranded RNA (dsRNA) as
5 specified in the attached claims, incorporated herein by reference.

Furthermore the invention provides methods for preventing, treating or alleviating NF-kappa-B dependent diseases whereby NF-kappa-B is believed to play a role in the pathogenesis of a disease in a subject, preferably a human, by
10 administration of a therapeutic effective and in a pharmacologically accepted form, the siRNA compounds of the invention.

BRIEF DESCRIPTION OF FIGURES

The invention will be described in closer detail in the following description, examples, and attached drawings, in which

15 Figure 1 shows the activity of endogenous NF-kappa-B in cells transfected with 4 siRNA compounds according to the invention;

Figure 2 shows the NF-kappa-B p65 subunit protein levels in 293 cells transfected with siRNA compounds; and

20 Figure 3 shows the results of Example 4 in the form of a histogram with different physiological criteria used to assess improvement in the degree of inflammation of the gastrointestinal tract after administration of an siRNA compound.

DESCRIPTION

Before the present method is disclosed and described, it is to be understood that this invention is not limited to the particular configurations, process steps, and materials disclosed herein, as such configurations, process steps, and materials may vary somewhat. It is also to be understood that the terminology employed herein is used for the purpose of describing particular embodiments only and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims and equivalents thereof.

Definitions

10 In describing, exemplifying and claiming the present invention, the following terminology will be used in accordance with the definitions set out below. Where not otherwise indicated, the terms are intended to have the meaning generally recognized in the art.

By "p65 subunit of NF-kappa-B" is meant any polynucleotide encoding the p65 subunit of NF-kappa-B.

By "p65 subunit of NF-kappa-B protein" is meant any p65 subunit of NF-kappa-B peptide or protein or a component thereof, wherein the peptide or protein is encoded by the p65 subunit of NF-kappa-B gene.

20 By "highly conserved sequence region" is meant a nucleotide sequence of one or more regions in a target gene, which does not vary significantly from one generation to the other or from one biological system to the other.

By "sense region" is meant a nucleotide sequence of a siNA molecule having complementarity to an antisense region of the siNA molecule. In addition, the sense region of a siNA molecule can comprise a nucleic acid sequence having homology with a target nucleic acid sequence.

By "antisense region" is meant a nucleotide sequence of a siNA molecule having complementarity to a target nucleic acid sequence. In addition, the antisense region of a siNA molecule can optionally comprise a nucleic acid sequence having complementarity to a sense region of the siNA molecule.

- 5 By "target nucleic acid" is meant any nucleic acid sequence whose expression or activity is to be modulated. The target nucleic acid can be DNA or RNA.

- By "complementarity" is meant that a nucleic acid can form hydrogen bond(-s) with another nucleic acid sequence by either traditional Watson-Crick or other non-traditional types or precise pairing, such that stable and specific binding
10 occurs between the oligonucleotide and the DNA or RNA target.

- By "modulate" and "modulation" is meant that the expression of the gene, or level of RNA molecule or equivalent RNA molecules encoding one or more proteins or protein subunits, or activity of one or more proteins or protein subunits is up regulated or down regulated, such that expression, level, or activity is greater
15 than or less than that observed in the absence of the modulator. For example, the term "modulate" can mean "inhibit" and within the scope of the invention, the preferred form of modulation is inhibition but the use of the word "modulate" is not limited to this definition.

- By "target site" is meant a sequence within a target RNA that is "targeted" or
20 cleavage mediated by a siNA construct which contains sequences within its antisense region that are complementary to the target sequence.

- By "inhibit" it is meant that the levels of expression product or level of RNAs or equivalent RNAs encoding one or more gene products is reduced below that observed in the absence of the nucleic acid molecule of the invention. In one
25 embodiment, inhibition with a siNA molecule preferably is below that level observed in the presence of an inactive or attenuated molecule that is unable to mediate an RNAi response.

By "gene" or "target gene" is meant a nucleic acid that encodes an RNA, for example, nucleic acid sequences including, but not limited to, structural genes encoding a polypeptide. The target gene can be a gene derived from a cell, an endogenous gene, a transgene, or exogenous genes such as genes of a pathogen, for example a virus, which is present in the cell after infection thereof. The cell containing the target gene can be derived from or contained in any organism, most preferably an animal. Non-limiting examples of animals include vertebrates and invertebrates. In the context of the invention, "gene" or "target gene" is most preferably the p65 subunit of NF-kappa-B.

By "RNA" is meant a molecule comprising at least one ribonucleotide residue. "ribonucleotide" is meant a nucleotide with a hydroxyl group at the 2' position of a D-ribo-furanose moiety. The terms include double-stranded RNA, single-stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as comprising non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides.

By "subject" is meant an organism, which is a donor or recipient of explanted cells or the cells themselves. "Subject" also refers to an organism to which the nucleic acid molecules of the invention can be administered. In one embodiment, a subject is a mammal or mammalian cells. In another embodiment, a preferred subject is a human subject or human cells.

The term "phosphorothioate" as used herein refers to an inter-nucleotide linkage comprising a sulfur atom in placement for an oxygen within the phosphate linkages of the sugar phosphate backbone. Hence, the term phosphorothioate refers to both phosphorothioate and phosphorodithioate inter-nucleotide linkages.

By "vectors" is meant any nucleic acid-and/or viral-based technique used to deliver a desired nucleic acid molecule inside a cell, biological system or organism.

By the term "non-nucleotide" is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is

5 abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine and therefore lacks a base at the 1'-position.

By "nucleotide" as used herein, is as recognized in the art to include natural bases (standard), and modified bases well known in the art. There are several

10 examples of modified nucleic acid bases known to a skilled person, such as those summarized by Limbach *et al.*, 1994, *Nucleic Acids Res.* 22, 2183.

The term "short interfering nucleic acid", "siNA", "short interfering RNA", "siRNA", "short interfering nucleic acid molecule", "short interfering oligonucleotide molecule", or "chemically-modified short interfering nucleic acid molecule" as

15 used herein refers to any nucleic acid molecule capable of mediating RNA interference "RNAi" or gene silencing in a sequence-specific manner.

The term "biodegradable linker" as used herein, refers to a nucleic acid or non-nucleic acid linker molecule that is designed as a linker molecule that is degradable by the surrounding milieu, inside a cell or organism and may be used

20 to connect one molecule to another molecule, for example, a biologically active molecule to a siNA molecule of the invention or the sense and antisense strands of a siNA molecule of the invention.

The term "biologically active molecule" as used herein, refers to compounds or molecules that are capable of eliciting or modifying a biological response in a

25 system

By "pharmaceutically acceptable formulation" is meant a composition or formulation that allows for the effective distribution of the nucleic acid molecules of the invention in that physical location most suitable for their desired activity.

By "systemic administration" is meant *in vivo* systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body

5 By "biological system" is meant material, in a purified or non-purified form, from biological sources, including but not limited to human, animal, plant, insect, bacterial, viral or other sources, wherein the system comprises the components required for RNAi activity.

10 By "phenotypic change" is meant any detectable change to a cell that occurs in response to contact or treatment with a nucleic acid molecule of the invention (e. g., siNA). Such detectable changes include, but are not limited to, changes in shape, size, proliferation, motility, protein expression or RNA expression or other physical or chemical changes as can be assayed by methods known in the art. The detectable change can also include expression of reporter genes/molecules such as Green Florescent Protein (GFP) or lucifersase or various tags that are
15 used to identify an expressed protein or any other cellular component that can be assayed.

Preferred embodiments of the invention

One embodiment of the invention provides a short interfering RNA (siRNA) molecule that down regulates expression of the p65 subunit of NF-kappa-B by
20 RNA interference. The siRNA molecule can be used to treat conditions associated with the expression of p65, for example cancer, allergic/inflammatory diseases and conditions, including but not limited to asthma, allergic rhinitis, atopic dermatitis, psoriasis, rheumatoid arthritis, ulcerative proctitis, ulcerative colitis, Crohn's disease, septic shock, and other diseases that are NF-kappa-B
25 dependent.

The siRNA molecule can comprise a sense region and an antisense region. The antisense region can comprise sequence complementary to an RNA sequence

encoding the p65 subunit of NF-kappa-B and the sense region can comprise sequence complementary to the antisense region.

- 5 An siRNA molecule can comprise a sense region and an antisense region and wherein said antisense region comprises sequence complementary to an RNA sequence encoding the p65 subunit of NF-kappa-B and the sense region comprises sequence complementary to the antisense region.

The siRNA molecule can be assembled from two nucleic acid fragments wherein one fragment comprises the sense region and the second fragment comprises the antisense region of said siRNA molecule.

- 10 The target region within the mRNA sequence encoding the p65 subunit of NF-kappa-B is preferably chosen among the sequences presented as SEQ.ID.NOs, 1, 2, 3, and 4. The target sequences were identified in human NF-kappa-B transcription factor p65 subunit mRNA, GenBank accession number M62399. See Table 1.



Table 1. NF-kappa-B target and siRNA compound sequences (5'-3')

Target Sequence		
SEQ ID NO	Sequence	Applicant's reference no.
1	AAGGACCUAUGAGACCUUCAA	IDX 101
2	AAGAUCAAUGGCUACACAGGA	IDX 105
3	AACACUGCCGAGCUCAAGAUC	IDX 106
4	GAGUCAGAUCAGCUCCUAAGG	IDX 107
Lower Sequence		
SEQ ID NO	Sequence	Applicant's reference no.
5	UUGAAGGUCUCAUAGGUCC(D)TT *	IDX 121
6	UCCUGUGUAGCCAUUGAUC(D)TT	IDX 125
7	GAUCUUGAGCUCGGCAGUG(D)TT	IDX 126
8	CCUUAGGAGCUGAUCUGAC(D)TT	IDX 127
Upper Sequence		
SEQ ID NO	Sequence	Applicant's reference no.
9	GGACCUAUGAGACCUUCAA(D)TT*	IDX 131
10	GAUCAAUGGCUACACAGGA(D)TT	IDX 135
11	CACUGCCGAGCUCAAGAUC(D)TT	IDX 136
12	GUCAGAUCAGCUCCUGGAA(D)TT	IDX 137

Notes:

- 5 * denotes that siRNA compound composed of antisense strand SEQ ID NO 5 annealed with sense strand SEQ ID NO 9 that was used in the animal proof of concept studies.

Compounds synthesized as RNA oligonucleotides with the last two nucleotides from the 3' end are DNA, denoted as (D).

The 3'-ends of the Upper sequence and the Lower sequence of the siRNA construct can include an overhanging sequence, for example 1, 2, 3, or 4 nucleotides in length, preferably 2 nucleotides in length, wherein the overhanging sequence of the lower sequence is optionally complementary to a portion of the target sequence. The upper sequence is also referred to as the sense strand, whereas the lower sequence is also referred to as the antisense strand.

The target region within the mRNA sequence encoding the p65 subunit of NF-kappa-B can comprise of sequences of up to 60 contiguous nucleotides containing entirely any of SEQ ID NOs, 1, 2, 3 and 4 within that 60 contiguous nucleotide stretch.

The antisense region of the p65 subunit of NF-kappa-B siRNA compound can comprise a sequence complementary to sequence chosen among SEQ ID NOs. 5, 6, 7 and 8.

The sense region of the p65 subunit of NF-kappa-B siRNA compound can comprise a sequence complementary to sequence chosen among SEQ ID NOs 9, 10, 11 and 12.

The sense region of the p65 subunit of NF-kappa-B siRNA compound preferably comprises the sequence of SEQ ID NO. 9, the corresponding antisense region of the p65 subunit of NF-kappa-B siRNA compound being SEQ ID NO. 5.

The sense region of the p65 subunit of NF-kappa-B siRNA compound preferably comprises the sequence of SEQ ID NO. 10, the corresponding antisense region of the p65 subunit of NF-kappa-B siRNA compound being SEQ ID NO. 6

The sense region of the p65 subunit of NF-kappa-B siRNA compound preferably comprises the sequence of SEQ ID NO. 11, the corresponding antisense region of the p65 subunit of NF-kappa-B siRNA compound being SEQ ID NO. 7.

The sense region of the p65 subunit of NF-kappa-B siRNA compound preferably comprises the sequence of SEQ ID NO. 12, the corresponding antisense region of the p65 subunit of NF-kappa-B siRNA compound being SEQ ID NO. 8.

5 Synthesis of nucleic acids greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs ("small" referring to nucleic acid motifs no more than 100 nucleotides in length, preferably no more than 80 nucleotides in length, and most preferably no more than 50 nucleotides in length; e. g., individual siNA oligonucleotide sequences or siNA sequences synthesized in
10 tandem) are preferably used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of protein and/or RNA structure.

The method of synthesis used for RNA including certain siNA molecules of the invention follows the procedure as described in Usman *et al.*, 1987, J. Am.
15 Chem. Soc., 109, 7845 ; Scaringe *et al.*, 1990, Nucleic Acids Res., 18, 5433.

The introduction of chemically modified nucleotides into nucleic acid molecules provides a powerful tool in overcoming potential limitations of *in vivo* stability and bioavailability inherent to native RNA molecules that are delivered exogenously. For example, the use of chemically modified nucleic acid molecules can enable a
20 lower dose of a particular nucleic acid molecule for a given therapeutic effect since chemically modified nucleic acid molecules tend to have a longer half-life in serum, such for example locked nucleic acids (LNA).

Furthermore, certain chemical modifications can improve the bioavailability of nucleic acid molecules by targeting particular cells or tissues and/or improving
25 cellular uptake of the nucleic acid molecule. Therefore, even if the activity of a chemically-modified nucleic acid molecule is reduced as compared to a native nucleic acid molecule, for example, when compared to an all-RNA nucleic acid molecule, the overall activity of the modified nucleic acid molecule can be greater

than that of the native molecule due to improved stability and/or delivery of the molecule. Unlike native unmodified siNA, chemically modified siNA can also minimize the possibility of activating interferon activity in humans.

- 5 The antisense region of a siNA molecule of the invention can comprise a phosphorothioate internucleotide linkage at the 3'-end of said antisense region. The antisense region can comprise about one to about five phosphorothioate internucleotide linkages at the 5'-end of said antisense region. The 3'-terminal nucleotide overhangs of a siNA molecule of the invention can comprise
- 10 ribonucleotides or deoxyribonucleotides that are chemically modified at a nucleic acid sugar, base, or backbone. The 3'-terminal nucleotide overhangs can comprise one or more universal base ribonucleotides. The 3'- terminal nucleotide overhangs can comprise one or more acyclic nucleotides. All modifications are well known in the art.
- 15 For example, an exemplary chemically modified siNA molecule of the invention comprises a duplex having two strands, one or both of which can be chemically modified with a chemical modifications known in the art.

- 20 In another embodiment, any modified nucleotides present in the siNA molecules of the invention, preferably in the antisense strand of the siNA molecules of the invention, but also optionally in the sense and/or both antisense and sense strands, comprise modified nucleotides having properties or characteristics similar to naturally occurring ribonucleotides.

- 25 In another embodiment, the conjugate is covalently attached to the chemically modified siNA molecule via a biodegradable linker. In one embodiment, the conjugate molecule is attached at the 3'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule.

In another embodiment, the conjugate molecule is attached at the 5'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified

siNA molecule. In yet another embodiment, the conjugate molecule is attached both the 3'-end and 5'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule, or any combination thereof.

- 5 Such conjugates and/or complexes can be used to facilitate delivery of siNA molecules into a biological system, such as a cell. The conjugates and complexes indicated by the invention can impart therapeutic activity by transferring therapeutic compounds across cellular membranes, altering the pharmacokinetics, and/or modulating the localization of nucleic acid molecules of
10 the invention. The use of such conjugates is well known in the art.

In one embodiment, the invention features a short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) inside a cell or reconstituted *in vitro* system, wherein one or both strands of the siNA molecule that are assembled from two separate oligonucleotides do not comprise any
15 ribonucleotides. All positions within the siNA can include chemically modified nucleotides and/or non- nucleotides.

In another embodiment, the, siNA of the p65 subunit of NF-kappa-B gene can be used to characterize pathways of gene function in a variety of applications by monitoring phenotypic changes. For example, the present invention can be used
20 to inhibit the activity of target gene (s) in a pathway to determine the function of uncharacterized gene (s) in gene function analysis, mRNA function analysis, or translational analysis. The invention can be used to determine potential target gene pathways involved in various diseases and conditions toward pharmaceutical development. The invention can be used to understand pathways
25 of gene expression involved in, for example, inflammation and other diseases and disorders.

In one embodiment, the invention features a composition comprising a siNA molecule of the invention, which can be chemically modified, in a

pharmaceutically acceptable carrier or diluent. In another embodiment, the invention features a pharmaceutical composition comprising siNA molecules of the invention, which can be chemically modified, targeting one or more genes in a pharmaceutically acceptable carrier or diluent.

- 5 In another embodiment, the invention features a method for treating or preventing a disease or condition in a subject, comprising administering to the subject most preferable a human a composition of the invention under conditions suitable for the treatment or prevention of the disease through which inhibition of the p65 subunit of NF-kappa-B is believed to be critical for the prevention of the disease
10 or condition in the subject.

The terms "short interfering nucleic acid", "siNA", "short interfering RNA", "siRNA", "short interfering nucleic acid molecule", "short interfering oligonucleotide molecule", or "chemically modified short interfering nucleic acid molecule" as used herein refers to any nucleic acid molecule capable of
15 mediating RNA interference (RNAi) or gene silencing in a sequence-specific manner.

The siNA molecules of the invention are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues. The nucleic acid or nucleic acid complexes can be locally
20 administered to relevant tissues *ex vivo*, or *in vivo* through injection, infusion pump or stent, with or without their incorporation in biopolymers.

In another aspect, the invention provides mammalian cells containing one or more siNA molecules of this invention. The one or more siNA molecules can
25 independently be targeted to the same or different sites.

The nucleic acid molecules of the instant invention, individually, or in combination or in conjunction with other drugs, can be used to treat diseases or conditions discussed herein (e. g., inflammation diseases, cancers and other conditions in

which NF-kappa-B plays a role). For example, to treat a particular disease or condition, the siNA molecules can be administered to a subject or can be administered to other appropriate cells evident to those skilled in the art, individually or in combination with one or more drugs under conditions suitable
5 for the treatment.

One embodiment of the invention is a method of preventing, treating or alleviating NF-kappa-B dependent conditions in an individual, which comprises the extraction of cells, tissue or entire organs from said individual; contacting the said cells, tissue or entire organs with a siRNA compound according to the invention,
10 so that expression of the p65 subunit of NF-kappa-B is suppressed, thereby suppressing NF-kappa-B dependent processes; and reintroducing the same cells, tissue or entire organ. Such method /methods may be used as a step in a treatment involving one of transplantation, graft, or implantation.

15 In a further embodiment, the siNA molecules can be used in combination with other known treatments to treat conditions or diseases discussed above. For example, the described molecules could be used in combination with one or more known therapeutic agents to treat a disease or condition. Non-limiting examples of other therapeutic agents that can be readily combined with a siNA
20 molecule of the invention are enzymatic nucleic acid molecules, allosteric nucleic acid molecules, antisense, decoy, or aptamer nucleic acid molecules, antibodies such as monoclonal antibodies, small molecules, and other organic and/or inorganic compounds including metals, salts and ions.

25 One embodiment of the invention provides an expression vector comprising a nucleic acid sequence encoding at least one siNA molecule of the invention in a manner that allows expression of the nucleic acid molecule. Another embodiment of the invention provides a mammalian cell comprising such an expression vector. The mammalian cell can be a human cell. The siNA molecule of the expression vector can comprise a sense region and an antisense region. The
30 antisense region can comprise sequence complementary to a RNA or a DNA

sequence encoding the p65 subunit of NF-kappa-B and the sense region can comprise sequence complementary to the antisense region. The siNA molecule can comprise two distinct strands having complementary sense and antisense regions. The siNA molecule can comprise a single strand having complementary
5 sense and antisense regions.

In one embodiment, the invention features an expression vector comprising a nucleic acid sequence encoding at least one siNA molecule of the invention, in a manner, which allows expression of the siNA molecule. For example, the vector can contain sequence (s) encoding both strands of a siNA molecule comprising a
10 duplex. The vector can also contain sequence (s) encoding a single nucleic acid molecule that is self- complementary and thus forms a siNA molecule.

The recombinant vectors capable of expressing the siNA molecules can be delivered as described herein, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of siNA molecules.
15 Such vectors can be repeatedly administered as necessary. Once expressed, the siNA molecules bind and down-regulate gene function or expression via RNA interference (RNAi). Delivery of siNA expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from a subject followed by reintroduction into said subject, or by
20 any other means that would allow for introduction into the desired target cell.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

EXAMPLES

The following are non-limiting examples showing the selection, isolation, synthesis and activity of nucleic acids of the instant invention.

Example 1. Construction of siNA compounds

- 5 In a non-limiting example, RNA oligonucleotides were synthesized in a stepwise fashion using the phosphoramidite chemistry known in the art.

All RNAs were purchased from Eurogentec Ltd (Liège, Belgium), and received as desalted powder. The sequence of RNAs is given in Table 1, wherein "upper sequence" denotes the sense sequence and "lower sequence" denotes the
10 antisense sequence. The last two nucleotides from the 3' end are synthesized as DNA nucleotides. The powder for each siNA molecule was dissolved in 100 mM potassium acetate, 30 mM HEPES-KOH, 2 mM magnesium acetate, pH 7.4 at a concentration of 100 μ M. The siRNA duplexes were formed by mixing equimolar concentrations at 50 μ M of SEQ ID N0. 9 with SEQ.ID.N0. 5, giving rise to
15 compound IDX 0131, SEQ ID N0. 10 with SEQ ID N0. 6, giving rise to compound IDX 0135, SEQ ID N0. 11 with SEQ ID N0. 7 giving rise to compound IDX 0136, and SEQ ID N0. 12 with SEQ ID N0. 8 giving rise to compound IDX 0137. See also Table 1.

- 20 The mixed samples were then heated to 90°C for 1 minute and incubated at 37°C for one hour to allow the two strands to anneal to each other. Each solution of annealed pairs was diluted to 20 μ M, aliquoted and stored frozen at -20°C until further use.

Example 2. Selection of potential siNA target sites in the RNA sequence of p65 subunit of NF-kappa-B

- 25 The sequence of an RNA target of interest, such as a viral or human mRNA transcript, is screened for target sites, for example by using a computer folding

algorithm. In a non-limiting example, the sequence of a gene or RNA gene transcript derived from a database, such as Genbank, is used to generate siNA targets having complementarity to the target. Such sequences can be obtained from a database, or can be determined experimentally as known in the art.

- 5 Target sites that are known, for example, those target sites determined to be effective target sites based on studies with other nucleic acid molecules, for example ribozymes or antisense, or those targets known to be associated with a disease or condition such as those sites containing mutations or deletions, can be used to design siNA molecules targeting those sites.
- 10 Various parameters can be used to determine which sites are the most suitable target sites within the target RNA sequence. These parameters include but are not limited to secondary or tertiary RNA structure, the nucleotide base composition of the target sequence, the degree of homology between various regions of the target sequence, comparison of homology between various
- 15 regions of the target sequence or highly conserved sequence regions derived from different species such as mouse rat or human, or indeed the relative position of the target sequence within the RNA transcript.

- 20 However, while there exists prediction methods, for example using a computer folding algorithms, that allow identification of a potential siNA target site within a target transcript, these methods provide no indication as to whether such sites are effective in achieving RNAi mediated inhibition of the target gene. As a consequence, considerable experimentation and an inventive approach is required to identify sites that demonstrate efficacy in a biological system.

- 25 The present inventor surprisingly identified four novel target sites implicated in NF-Kappa-B subunit p65 expression and developed active and specific siNA molecules to these sites.

The following non-limiting steps can be used to carry out the selection of siNAs targeting the p65 subunit of NF-kappa-B mRNA transcript.

A collection of sequence specific siNA compounds designed to target human p65 subunit of NF-kappa-B mRNA where screened for efficacy in cells that contained a luciferase reporter construct.

5 The use of such luciferase reporter constructs is well know in the art and provides a simple means to determine the degree of activity of a particular gene of interest depending on the design of the construct used. In the scope of the present invention the particular construct employed was designed such that it was sensitive to the levels of endogenous active NF-kappa-B. In other words, the construct contained typical "NF-kappa-B binding sites" as discrete genetic
10 elements such that active NF-kappa-B would bind to said elements and induce the expression of the reporter gene luciferase. Higher levels of NF-kappa-B would be indicative of higher levels of luciferase activity within a cell. Conversely, lower levels of NF-kappa-B would be indicated of lower levels of luciferase activity.

15 It follows, that by introduction into such cells harboring the luciferase construct, of the siRNA compounds designed to target the mRNA encoding the p65 subunit of NF-kappa-B, those compounds that demonstrate efficacy will result in decreased levels of mRNA encoding the p65 subunit of NF-kappa-B as mediated by the RNAi effect and therefore decreased levels of p65 protein. As NF-kappa-B exists
20 and functions as a heterodimer of two proteins, namely p50 and p65, reduction in the levels of p65 protein will result in reduced NF-kappa-B activity. This reduction can be monitored using said luciferase reporter constructs.

25 The target sequences corresponding to SEQ ID NOs. 9, 10, 11 and 12 were identified, as well as the antisense sequences corresponding to SEQ ID NOs. 5, 6, 7 and 8 developed by the present inventors.

Cells expressing the luciferase construct (e. g., 293 cells) are transfected with the collection of siNA compounds (ID.N0 IDX 0131, ID.N0 IDX 0135, ID.N0 IDX 0136 and ID.N0 IDX 0137 and the levels of luciferase activity is monitored. In

detail, on the day before transfection, 293 cells were harvested and distributed into 24 well plates at 0.1×10^6 cells per well. On day 0, cells were transfected with siRNA as follows (description refers to a single group of transfection) 4.5 ul of oligofectamine was diluted in 18 ul of Optimem I medium (Invitrogen) and
 5 incubated for 5 min at room temperature 7.5 ul of respective siRNA (20 uM) were diluted in 120 ul of Optimem I medium and directly afterwards were mixed with Oligofectamine solution. Oligofectamine/siRNA complexes were formed for 20 minutes at room temperature.

During this incubation cell culture medium was replaced to 200 ul of serum-free
 10 Minimal essential medium per well (4 well per group). Medium exchange was done by removing medium with 1 ml tip and then directly adding serum-free medium with another pipette to minimize drying out.

Oligofectamine/siRNA complexes were added at 50 ul per well. Thereafter cells were incubated in transfection mixture for 6 hours at 37°C supplemented with 5%
 15 CO₂. On day 2 after transfection, cells from 2 wells were trypsinized and transferred to 3 wells in 24 well cultures. On day 3 cells were transfected with a cocktail containing 0.01ug NF-kappa-B reporter plasmid and 0.03 ug/well of beta-galactosidase plasmid. Transfection was performed using Fugene 6 (Roche) as a transfection agent at the ratio 2 ug of DNA/ 3 ul of Fugene 6 and following
 20 manufacturer's instructions. On day 4 (16 hours after reporter transfection) 25 ng/ml of TNF were added to stimulate the cell cultures.

On reporter assays were performed after 24 hours following transfection on day 5, using Luciferase detection part of Dual-Luciferase reporter system (Promega).

As is evident from Fig. 1, the cells that received no siRNA compound show a high
 25 luciferase activity, whereby cells that were transfected with siRNA compounds IDX 0131, IDX 0135, IDX 0136 and IDX 0137 demonstrate functional siRNA compounds in that the activity of luciferase is reduced. This is most markedly seen with compound IDX 0135, the rank order of potency being IDX 0135 > IDX

0137 > IDX 0131 > IDX 0136. Transfection of cells using siRNA compounds of unrelated sequences caused only a very small reduction of luciferase activity and can be largely attributed to unspecific effects a phenomenon that has been observed and reported by many researchers in the field.

5 Example 3. Determination of inhibitor effects *in vitro* of the siRNA compounds on the p65 subunit of NF-kappa-B

Cells were treated as described in Example 1. On day 4, the medium was removed and cells were lysed in 50 µl of lysis buffer (20 mM Tris pH 7.5, 1% TritonX-100, 1mM EDTA, 150 mM NaCl, 1mM EDTA, 1 mM PMSF, Aprotinin and
10 Leupeptin) for 20 minutes on ice. Thereafter, lysates were transferred to 1.5 ml Ependers tubes and centrifuged for 10 min at 14,000 rpm to remove cellular debris and nuclei. Thereafter, 40 µl of lysates were combined with 40 µl of reduced Laemli sample buffer for SDS-PAGE and incubated at 95°C for 5 min.
20 µl of each sample were loaded per well. After electrophoresis, proteins were
15 blotted to nitrocellulose membranes using mini-cell blotting apparatus (Biorad). The membranes were blocked in 5% non-fat milk and then were incubated with antibodies directed to p65 (Santa Cruz, sc-372) for 1 hour followed by HRP-coupled anti-rabbit reagent (Amersham Biosciences, NA934V) for one hour.

Thereafter membranes were developed using ECL detection reagent (Amersham
20 Biosciences, RPN2106V1).

All antibodies were applied diluted 1 to 1000 in Tris-buffered saline (pH 7.5) containing 5% of non-fat dry milk and 0.05% Tween-20. To confirm equal loading, membranes were subsequently incubated with antibodies to human b-actin (Santa Cruz, I-19) and HRP-coupled rabbit anti-goat antibodies (DAKO,
25 P0449) using procedures described above.

From Fig. 2 it is evident that siRNA compounds IDX 0131, IDX 0135 and IDX 0137 are able to down regulate the expression of the p65 subunit of NF-kappa-B protein to levels of near non detection when compared to levels of p65 protein in

cells in the absence of siRNA compound. In contrast, siRNA compound IDX 0136 was only able to produce a moderate down regulation of the p65 protein level. These results are in good agreement to those described in Example 2.

Example 4. Suppression of inflammation in a colitis mouse model using siRNA compound IDX 0131 designed to inhibit NF-kappa-B p65 subunit

- 5
- An animal model wherein inflammation is induced in the large intestine of mice has been described by Okayasu *et al.*, 1990. In the model used in the present experiment, oral dextran sulfate sodium (DSS) was employed to induce inflammation (Axelsson, *et al.*, 1998). DSS can be given to the mice in the
- 10 drinking water, thereby inducing a colitis resembling inflammatory bowel disease (IBD) in man. An MW of about 40-50 kD and an high content of up to about 19% sulphur has been shown to be optimal for the inflammation inducing form of DSS. In Okayasu, 1990, the DSS was given to the animals at a concentration of about 2-5%.
- 15 In this study DSS was used at a concentration of 2.5%, dissolved in water, with a final pH of 8.5 (adjusted with NaOH). DSS was given orally to female SPF NMRI mice for 8 consecutive days to induce a stable colitis in all individuals. This type of experimentally induced colitis has been shown to be fully induced at day 4-5 after addition in the drinking water (Cooper *et al.*, 1993).
- 20 The siRNA substance, as given by IDX 0131 was administered rectally to non-medicated or anaesthetized colitic animals. A shortened XRO feeding tube (Vygon, Ecouen, France) was inserted rectally, up to the level of the ligament of Treitz, and the substance, in a final volume of 100 ul, was administered during slow careful retraction of the tubing to avoid rectal leakage of the substance.
- 25 Two groups of animals were used in this study, one group received a single dose of 10uM of siRNA compound IDX 0131 comprising SEQ ID NO. 5 and SEQ ID NO. 9 in 100ul of water. The other group

received a single dose of 40 uM of siRNA compound IDX 0131 comprising SEQ ID NO. 5 and SEQ ID NO. 9 in 100ul water.

Therapeutic treatment was given once on day 8 while the DSS treatment continued another 10 days. On day 18 the animals were killed and subjected to
5 analysis of clinical inflammatory parameters and histopathological examinations.

Clinical signs

Each mouse was observed once daily during the study period. All signs of bad health and any behavioral changes were recorded. Animals showing severe signs of disease and losing more than 15% of its original body weight were killed.

10 *Mortality and necropsy*

Mortality during the experimental period was recorded. At the end of the experimental period, animals were killed by dislocation of the cervical spine. The abdomen was opened and the spleen was resected and weighed. The large intestine was excised from the ileocecal junction to the proximal rectum, close to
15 its passage under the pelvisternum. The caecum was opened at the apex and feces were carefully removed. The colon was opened longitudinally and the feces were carefully removed with a spatula. Evaluation of colitis was made by recording clinical parameters such as mortality, colon length, spleen weight and diarrhea, calculated as wet/dry weight of the feces after drying 48h at 60°C
20 (Figure 2). The entire caecum and colon were fixed in 4% neutral buffered formaldehyde for microscopic examination.

It is evident from Figure 2 that there is a specific and significant improvement in all measured parameters. That is to say, treated animals had less diarrhea, had a more normal colon length, a more normal spleen weight and showed statistically
25 significant signs of histological improvement.

Processing and microscopic examination

After fixation, the tissues sampled for microscopic examination were trimmed and specimens were taken from caecum and the mid portion of colon for histological processing. Additional specimens were taken when the first sample was difficult
5 to interpret. The specimens were embedded in paraffin and cut at a nominal thickness of 5 µm, stained with haematoxylin and eosin, and examined under light microscope.

Verification of colitis and estimation of inflammation was performed by an experienced veterinary pathologist, having extensive experience of the
10 histopathological evaluation of DSS-induced colitis in mice. Diagnostic histopathology is based on a standardized grading system shown in Table 2.

Table 2. Histopathologic grading system

Colitis lesions:	
+/-	very mild (may be normal)
+	mild
++	moderate
+++	severe
++++	very severe

Histological analysis of colonic sections

15 As outlined above, sections taken from the caecum and the mid portion of the colon were used for histological processing. Staining was performed with haematoxylin and eosin. Sections were then examined by light microscopy and morphological changes noted.

From Fig. 3 it can be concluded that a single rectal administration of antisense compound as given by compound IDX 0131 comprising SEQ ID NO 5 and SEQ ID NO. 9 was sufficient to dramatically reduce the degree of inflammation as seen on all three physiological parameters.

- 5 In Fig. 3, a black solid bar denotes healthy animals that received only standard drinking water (healthy control). The unfilled bar denotes colitis induced animals who receive 2.5% DSS in their drinking water which will induce inflammation of the colon (sick control). The light grey bar denotes those animals who received in addition to DSS in their drinking water,
10 siRNA compound IDX 0131 at a final concentration of 10uM. Lastly, the dark grey bar denotes those animals who received in addition to DSS in their drinking water, siRNA compound IDX 0131 at a final concentration of 40uM. The beneficial effects seen with higher concentrations of siRNA compound IDX 0131 are less pronounced and indicate a possible
15 therapeutic threshold lower than 40uM.

It is evident that a single rectal administration of siRNA compound as given by compound IDX 0131 demonstrated clear signs of clinical improvement in colitis mice. This is most evident at a compound concentration of 10uM with levels of statistical relevance of ($P < 0.005$).

- 20 With respect to all three parameters, a dose of 10uM siRNA compound IDX 0131 improved dramatically the degree of diarrhoea, colon length and spleen weight to values near those seen in healthy controls (compare black bars to light grey bars).

- 25 The most effective dose appeared to be the lower of the two used in the study and indicate a possible therapeutic threshold of lower than 40uM. Moreover, it is indeed well know in the art that NF-kappa-B while critical for

the development and maintenance of an inflammatory phenotype is equally important in processes or rebuilding of damaged tissue as a result of inflammation. Consequently, there may be a need to establish the correct amount of inhibition of NF-kappa-B.

- 5 These results provide strong proof that by reducing the levels of NF-kappa-B beneficial effects regarding course and degree of inflammation are achieved. Moreover, the experiment also demonstrates that such diseases and indeed other diseases whereby NF-kappa-B is a critical factor in the pathogenesis of such diseases can be addressed using siRNA technology.
- 10 All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.
- 15 One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein
- 20 and other uses that will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims.

In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual

25 member or subgroup of members of the Markush group or other group.

REFERENCES

Axelsson, *et al.*, 1998, Aliment Pharmacol Ther, 12:925-34

Beach *et al.*, WO 01/68836

Cooper, *et al.*, 1993, Lab Invest, 69:238-49

5 Jensen, *et al.*, 1999, Nat Genet 21:209-12

Ketting, *et al.*, 1999, Cell, 99:133-41

Kreutzer *et al.*, WO 00/44895

Limbach *et al.*, 1994, Nucleic Acids Res. 22, 2183.

Okayasu, *et al.*, 1990, Gastroenterology, 98:694-702

10 Ratcliff, *et al.*, 1999, Plant Cell, 11:1207-16

Scaringe *et al.*, 1990, Nucleic Acids Res., 18, 5433.

Tabara, *et al.*, 1999, Cell 99:123-32

15 Usman *et al.*, 1987, J. Am. Chem. Soc., 109, 7845

20

25

CLAIMS

1. A short interfering RNA (siRNA) molecule that down regulates expression of an p65 subunit of NF-kappa-B gene by RNA interference, said siRNA molecule comprising a sense region and an antisense region and wherein said antisense region comprises sequence complementary to an RNA sequence encoding the p65 subunit of NF-kappa-B and the sense region comprises sequence complementary to the antisense region, **characterized** in that said antisense region comprises a sequence substantially complementary to a sequence chosen among SEQ ID NOs. 1, 2, 3 and 4.
2. The siRNA molecule of claim 1, wherein said sense region and antisense region are covalently connected via a linker molecule.
3. The siRNA molecule of claim 1, wherein said linker molecule is a polynucleotide linker.
4. The siRNA molecule of claim 1, wherein said linker molecule is a non-nucleotide linker.
5. The siRNA molecule of claim 1, wherein said antisense region comprises a sequence chosen among SEQ ID NOs. 5, 6, 7 and 8.
6. The siRNA molecule of claim 1, wherein said sense region comprises a sequence chosen among SEQ ID NOs 9, 10, 11 and 12.
7. The siRNA molecule of claim 1, wherein said sense region comprises the sequence of SEQ ID NO. 9 and said antisense region comprises the sequence of SEQ ID NO. 5.
8. The siRNA molecule of claim 1, wherein said sense region comprises the sequence of SEQ ID NO. 10 and said antisense region comprises a sequence of SEQ ID NO. 6.

9. The siRNA molecule of claim 1, wherein said sense region comprises the sequence of SEQ ID NO. 11 and said antisense region comprises the sequence of SEQ ID NO. 7.
10. The siRNA molecule of claim 1, wherein said sense region comprises the sequence of SEQ ID NO. 12 and said antisense region comprises the sequence of SEQ ID NO. 8.
11. The siRNA molecule of any one of claims 1 – 10, wherein said sense region comprises a 3'-terminal overhang and said antisense region comprises a 3'-terminal overhang.
12. The siRNA molecule of claim 11, wherein said 3'-terminal overhangs each comprising 1 to 5 natural or modified nucleotides.
13. The siRNA molecule of claim 11, wherein said antisense region 3'-terminal nucleotide overhang is complementary to RNA encoding p65 subunit of NF-kappa-B.
14. The siRNA molecule of claim 1, wherein said sense region comprises one or more 2'-O-methyl modified pyrimidine nucleotides.
15. The siRNA molecule of claim 1, wherein said sense strand comprises a terminal cap moiety at the 5'-end, 3'-end, or both 5' and 3' ends of said sense region.
16. The siRNA molecule of claim 1, wherein said antisense strand comprises one or more 2'-deoxy-2'-fluoro modified pyrimidine nucleotides.
17. The siRNA molecule of claim 1, wherein said antisense and/or sense strand comprises between one and up to and including five phosphorothioate internucleotide linkages at the 3' end of said antisense region.

18. The siRNA molecule of claim 1, wherein said antisense and/or sense strand comprises between one and up to and including five phosphorothioate internucleotide linkages at the 5' end of said antisense region.

19. The siRNA molecule of claim 11, wherein said 3'-terminal nucleotide overhangs comprise ribonucleotides that are chemically modified at a nucleic acid sugar, base, or backbone.

20. The siRNA molecule of claim 11, wherein said 3'-terminal nucleotide overhangs comprise deoxyribonucleotides that are chemically modified at a nucleic acid sugar, base, or backbone.

21. The siRNA molecule of claim 11, wherein said 3'-terminal nucleotide overhangs comprise one or more universal base ribonucleotides.

22. The siRNA molecule of claim 11, wherein said 3'-terminal nucleotide overhangs comprise one or more acyclic nucleotides.

23. The siRNA molecule of claim 11, wherein said 3'-terminal nucleotide overhangs comprise nucleotides or non-nucleotides

24. An expression vector comprising a nucleic acid sequence encoding at least one siRNA molecule of claim 1 in a manner that allows expression of the nucleic acid molecule.

25. A mammalian cell comprising the expression vector of claim 24.

26. The mammalian cell of claim 25, wherein said mammalian cell is a human cell.

27. The expression vector of claim 24, wherein said siRNA molecule comprises a sense region and an antisense region and wherein said antisense region comprises sequence complementary to an RNA sequence encoding p65 subunit

of NF-kappa-B and the sense region comprises sequence complementary to the antisense region.

28. The expression vector of claim 24, wherein said siRNA molecule comprises two distinct strands having complementarity sense and antisense regions.

5 29. The expression vector of claim 24, wherein said siRNA molecule comprises a single strand having complementary sense and antisense regions.

30. A method of preventing, treating or alleviating NF-kappa-B dependent conditions in an individual, which comprises administering a therapeutically effective amount and in a suitable pharmacological carrier, a siRNA compound of
10 claim 1, so that expression of the p65 subunit of NF-kappa-B is suppressed, thereby suppressing NF-kappa-B dependent processes.

31. The method of claim 30, wherein the NF-kappa-B dependent condition is selected from cancer, cardiac disorders, ischaemia, allergic/inflammatory diseases and conditions, including but not limited to asthma, allergic rhinitis,
15 atopic dermatitis, psoriasis, rheumatoid arthritis, ulcerative proctitis, ulcerative colitis, Crohn's disease, septic shock, and other diseases or conditions that are NF-kappa-B dependent.

32. A method of preventing, treating or alleviating NF-kappa-B dependent conditions in an individual, which comprises the extraction of cells, tissue or
20 entire organs from said individual; contacting the said cells, tissue or entire organs with a siRNA compound of claim 1, so that expression of the p65 subunit of NF-kappa-B is suppressed, thereby suppressing NF-kappa-B dependent processes; and reintroducing the same.

33. The method of claim 32, wherein said method is used as a step in a
25 treatment involving one of transplantation, graft, or implantation.


ABSTRACT

This invention relates to compounds, compositions, and methods useful for modulating the expression and activity of NF-kappa-B by RNA interference (RNAi) using small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA) and double-stranded RNA (dsRNA).
 5 Furthermore the invention provides methods for preventing, treating or alleviating NF-kappa-B dependent diseases whereby NF-kappa-B is believed to play a role in the pathogenesis of a disease in a subject, preferably a human, by administration of a therapeutic effective and in a pharmacologically accepted
 10 form, the siRNA compounds of the invention.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
217

Fig. 1

Activity of endogenous NF-kappa-B in 293 cells transfected with 4 siNA compounds



MH 51390

2/3

Fig. 2

Levels of NF-kappa-B p65 protein in 293 cells in the presence and absence of p65 siRNA compounds




Fig. 3

Efficacy of siRNA compound ID-N0, IDX 0131 in colitis mice

